Effects of imidazole-2-hydroxibenzoate on glycosaminoglycan and albumin urinary excretion in type 1 diabetic patients

Nephron. 1988;50(1):45-9. doi: 10.1159/000185115.

Abstract

The effect of imidazole-2-hydroxibenzoate on urinary excretion rates of glycosaminoglycans and albumin in 22 insulin-dependent diabetics with albumin excretion rates under 300 mg/day was evaluated in a 165-day double blind crossover study. Unlike placebo, the drug reduced glycosaminoglycan and albumin excretion rates significantly after 40 and 60 days of treatment, and the effects were significantly intercorrelated. Moreover, a parallel reduction in urinary excretion of N-acetyl-beta-D-glucosaminidase was also observed. These pharmacological effects may have a positive impact on the subsequent natural history of diabetic nephropathy.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Acetylglucosaminidase / urine
  • Adolescent
  • Adult
  • Albuminuria*
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Diabetes Mellitus, Type 1 / urine*
  • Female
  • Glycosaminoglycans / urine*
  • Humans
  • Imidazoles / pharmacology*
  • Male
  • Middle Aged
  • Salicylates / pharmacology*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Glycosaminoglycans
  • Imidazoles
  • Salicylates
  • imidazole-2-hydroxybenzoate
  • Acetylglucosaminidase